MAIA Biotechnology (MAIA) Enterprise Value (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Enterprise Value of -$34.4 million for Q1 2026, down 216.78% year-over-year from $29.5 million in Q1 2025, and down 297.47% quarter-over-quarter from -$8.7 million in Q4 2025.
MAIA Biotechnology (MAIA) Enterprise Value (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Enterprise Value for 6 consecutive years, with -$34.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 216.78% year-over-year to -$34.4 million; the TTM figure through Mar 2026 stood at -$34.4 million (down 216.78% YoY), while the FY2025 annual figure was -$8.7 million, up 9.82% from the prior year.
- Enterprise Value declined to -$34.4 million in Q1 2026 per MAIA's latest filing, from -$8.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$6.1 million in Q3 2023 and bottomed at -$34.4 million in Q1 2026.
- Historically, Enterprise Value has averaged -$11.0 million across 5 years, with a median of -$9.4 million in 2023.
- Annual changes were most pronounced in 2023 — Enterprise Value soared 56.59% — and 2026, when it plunged 216.78%.
- MAIA Biotechnology's Enterprise Value stood at -$11.0 million in 2022, then jumped by 34.7% to -$7.2 million in 2023, then plunged by 34.27% to -$9.6 million in 2024, then grew by 9.82% to -$8.7 million in 2025, then tumbled by 297.47% to -$34.4 million in 2026.
- Business Quant data shows MAIA's Enterprise Value at -$34.4 million in Q1 2026, -$8.7 million in Q4 2025, and -$10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | -27.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.60 Mn |
| Mar 31, 2026 | -34.41 Mn |
| Dec 31, 2025 | -8.66 Mn |
| Sep 30, 2025 | -10.89 Mn |
| Mar 31, 2025 | -10.86 Mn |
| Dec 31, 2024 | -9.60 Mn |
| Sep 30, 2024 | -8.69 Mn |
| Jun 30, 2024 | -11.58 Mn |
| Mar 31, 2024 | -8.27 Mn |
| Dec 31, 2023 | -7.15 Mn |
| Sep 30, 2023 | -6.10 Mn |
| Jun 30, 2023 | -9.15 Mn |
| Mar 31, 2023 | -7.59 Mn |
| Dec 31, 2022 | -10.95 Mn |
| Sep 30, 2022 | -14.06 Mn |
| Jun 30, 2022 | -8.15 Mn |
| Mar 31, 2022 | -10.29 Mn |
| Dec 31, 2021 | -10.57 Mn |
| Sep 30, 2021 | -10.95 Mn |
| Jun 30, 2021 | -6.78 Mn |